Edition:
United States

Cerus Corp (CERS.O)

CERS.O on Consolidated Issue listed on NASDAQ Global Market

6.57USD
22 Jul 2016
Change (% chg)

$0.07 (+1.08%)
Prev Close
$6.50
Open
$6.53
Day's High
$6.61
Day's Low
$6.48
Volume
668,519
Avg. Vol
1,137,022
52-wk High
$6.89
52-wk Low
$4.27

Summary

Name Age Since Current Position

Daniel Swisher

52 2013 Independent Chairman of the Board

William Greenman

48 2011 President, Chief Executive Officer, Director

Kevin Green

43 2013 Chief Financial Officer, Vice President - Finance

Caspar Hogeboom

56 2012 President, Cerus Europe and EEMEA

Laurence Corash

71 2009 Senior Vice President, Chief Medical and Chief Scientific Officer, Director

Carol Moore

65 2013 Senior Vice President - Regulatory Affairs, Quality and Clinical

Richard Benjamin

2015 Chief Medical Officer

Chrystal Menard

44 2012 Chief Legal Officer and General Counsel

Timothy Anderson

68 2003 Independent Director

Bruce Cozadd

51 2001 Independent Director

Gail Schulze

63 2007 Independent Director

Franklin Witney

61 2014 Independent Director

Lainie Corten

Sr. Director, Global Marketing & Investor Relations

Biographies

Name Description

Daniel Swisher

Mr. Daniel N. Swisher, Jr., is an Independent Chairman of the Board of Cerus Corporation., effective October 21, 2013. Mr. Swisher continues to be a valuable member of the Board in part due to his extensive financial management expertise as the former Chief Financial Officer of Sunesis Pharmaceuticals, Inc., or Sunesis, and his industry expertise as the current President and Chief Executive Officer of Sunesis. Mr. Swisher has served as the Chief Executive Officer of Sunesis and a member of its board of directors since January 2004 and as its President since August 2005. From December 2001 to December 2003, he served as the Chief Business Officer and Chief Financial Officer of Sunesis. From June 1992 to September 2001, Mr. Swisher served in various management roles, including Senior Vice President of Sales and Marketing, for ALZA Corporation.

William Greenman

Mr. William M. Greenman is President, Chief Executive Officer, Director of Cerus Corporation. The Nominating and Corporate Governance concluded that Mr. Greenman should continue to serve as a member of the Board in part due to his knowledge of day-to-day operations obtained as a result of his various executive roles at Cerus over the last fifteen years. Mr. Greenman has a broad depth of experience and historical knowledge regarding Cerus’ clinical, commercial and regulatory pathways. Mr. Greenman served as our Senior Vice President, Business Development and Marketing from August 2008 until April 2011 and was named our Chief Business Officer in April 2010. Mr. Greenman served as our President, Cerus Europe, from 2006 until August 2008. From 1999 to 2006, Mr. Greenman served as our Vice President, Business Development after returning to Cerus after a brief time in the venture capital business. Prior to joining us in 1995 as Director of Business Development, Mr. Greenman worked in various marketing and business development positions in Baxter’s Biotech Division from 1991 to 1995. Mr. Greenman has served on the board of directors of Aduro Biotech, Inc., a clinical-stage immuno-oncology company, since June 2010.

Kevin Green

Mr. Kevin D. Green is Chief Financial Officer, Vice President - Finance of Cerus Corporation. He was appointed company's Vice President, Finance and Chief Financial Officer in February 2013. Prior to that, Mr. Green served as our Vice President, Finance and Chief Accounting Officer, a role to which he was appointed in March 2009. From January 2006 to March 2009, Mr. Green was our Senior Director of Finance and Controller. From 2000 until 2006, Mr. Green held various financial management positions with Macromedia, Inc., a software company acquired by Adobe Systems in 2005, including Director of Finance and Assistant Controller. Prior to joining Macromedia, Mr. Green was a member of PricewaterhouseCoopers LLP in the Assurance and Business Advisory Services division.

Caspar Hogeboom

Mr. Caspar Hogeboom is President, Cerus Europe and EEMEA of Cerus Corporation. Prior to that, Mr. Hogeboom was Managing Director of Cerus Europe from November 2008 to February 2011 and General Manager of Cerus Europe from February 2011 to February 2012. From March 2006 to November 2008, Mr. Hogeboom served as our Managing Director Europe, INTERCEPT Blood Systems and was responsible for sales and marketing at Cerus Europe. Prior to joining Cerus in 2006, Mr. Hogeboom worked for Baxter Healthcare in Europe, where he held several management, sales and marketing positions from 1992 to 2006. Prior to joining Baxter, Mr. Hogeboom held various sales and marketing positions at Maxxim Medical in the Netherlands.

Laurence Corash

Dr. Laurence M. Corash, M.D., is Senior Vice President, Chief Medical and Chief Scientific Officer, Director of Cerus Corporation. Dr. Corash continues to be a valuable member of the Board in part due to his extensive knowledge of us, having been a director since 2002, which brings historic knowledge and continuity to the Board. The Board also considered his scientific expertise obtained from almost 30 years as an M.D. in the field of hematology, which is relevant to our pathogen reduction technology for blood products. Dr. Corash has been our Senior Vice President and Chief Medical and Chief Scientific Officer since July 2009. Previously, he had been our Senior Vice President and Chief Medical Officer since March 2008. Prior to that, he had been our Vice President, Medical Affairs since July 1996 and Director of Medical Affairs from July 1994. Dr. Corash was a consultant to us from 1991 until 1994, when he joined us as Director, Medical Affairs. Dr. Corash has been a Professor of Laboratory Medicine at the University of California, San Francisco since July 1985. He was the Chief of the Hematology Laboratory for the Medical Center at the University of California, San Francisco from 1982 to 1997. From February 1990 to July 1994, Dr. Corash was a member of the FDA Advisory Panel for Hematology Devices. From 2008 until 2011, Dr. Corash served as the industry representative on the Department of Health and Human Services’ Advisory Committee on Blood Safety and Availability.

Carol Moore

Ms. Carol M. Moore is Senior Vice President - Regulatory Affairs, Quality and Clinical of Cerus Corp. From April 2008 to February 2013, Ms. Moore was our Vice President, Regulatory Affairs, Quality and Clinical. Prior to joining Cerus, Ms. Moore served in various roles at Bayer Corporation, most recently as Vice President, Worldwide Regulatory Affairs, for over 30 years focusing on the registration and regulatory compliance of Bayer’s biological and biotech products, health policy, and strategic planning.

Richard Benjamin

Dr. Richard J. Benjamin, MD PhD is Chief Medical Officer of the Company. Benjamin served as Chief Medical Officer of the American Red Cross since 2006. He is a board member and regional director for North America for the International Society of Blood Transfusion, as well as an active member of the AABB. He is an adjunct associate professor of pathology at Georgetown University in Washington, DC, and has served on the US Department of Health and Human Service's Advisory Committee on Blood Safety and Availability. Prior to joining the Red Cross, Dr. Benjamin was a medical director at the Adult Transfusion Service at the Joint Program in Transfusion Medicine at Harvard University. He received his PhD in immunology from Cambridge University in England, and completed his post-doctoral research at Stanford University. Dr. Benjamin's medical degree is from the University of Cape Town, South Africa.

Chrystal Menard

Ms. Chrystal N. Menard has been appointed as the Chief Legal Officer of Cerus Corporation., effective from December 3, 2012. Ms. Menard was Senior Corporate Counsel at Zynga Inc. Prior to August 2011, Ms. Menard was a partner of the law firm presently named Cooley LLP, practicing corporate and securities law.

Timothy Anderson

Mr. Timothy Bruce Anderson is an Independent Director of Cerus Corporation. The Nominating and Corporate Governance Committee concluded that Mr. Anderson should continue to serve as a member of the Board in part due to his extensive knowledge of us, having been a director since 2003, which brings historic knowledge and continuity to the Board. The Board also considered his operational and global industry experience obtained from his many years as an executive with Baxter International. Mr. Anderson was Senior Vice President of Strategy and Business Development of Baxter International, Inc., a pharmaceutical company, from 1999 until 2002, and held various management positions at Baxter International from 1992 until 1999, including President, Biotech Group from 1992 until 1997, Group Vice President from 1993 until 1997 and Chairman, Baxter Europe from 1997 until 1999. From 2006 until 2010, Mr. Anderson served as a member of the board of directors of Puricore Public Limited Company.

Bruce Cozadd

Mr. Bruce C. Cozadd is an Independent Director of Cerus Corporation., since November 2001 The Nominating and Corporate Governance Committee concluded that Mr. Cozadd should continue to serve as a member of the Board in part due to his extensive financial management expertise as the former Chief Financial Officer of ALZA Corporation and his industry expertise as the Chairman and Chief Executive Officer of Jazz Pharmaceuticals plc. This expertise has also led the Board to determine that he is an “audit committee financial expert” as defined the by the SEC. The Board also believes that because Mr. Cozadd has been a director since 2001, he brings historic knowledge and continuity to the Board. Mr. Cozadd is a co-founder of Jazz Pharmaceuticals, Inc. and has served as its Chairman and Chief Executive Officer since April 2009. In January 2012, Mr. Cozadd became the Chairman and Chief Executive Officer of Jazz Pharmaceuticals plc, the successor to Jazz Pharmaceuticals, Inc. From 2003 until April 2009, he served as Executive Chairman of Jazz Pharmaceuticals, Inc. From 1991 until 2001, he held various positions with ALZA Corporation, a pharmaceutical company now owned by Johnson & Johnson, most recently as its Executive Vice President and Chief Operating Officer, with responsibility for research and development, manufacturing and sales and marketing and prior to that as Chief Financial Officer and Vice President, Corporate Planning and Analysis. Previously, Mr. Cozadd was a member of the health care investment banking team at Smith Barney, Harris Upham & Co. He serves on the boards of Jazz Pharmaceuticals plc, Threshold Pharmaceuticals, Inc., a biotechnology company, and The Nueva School, a non-profit organization.

Gail Schulze

Ms. Gail Gaumer Schulze is an Independent Director of Cerus Corporation. The Nominating and Corporate Governance Committee concluded that Ms. Schulze continues to be a valuable member of the Board in part due to her extensive experience in executive roles in both large and small life sciences organizations at various stages of development. From May 2008 until June 2012, she was the Chief Executive Officer and Chairman of the Board of Directors of Zosano Pharma, a private biopharmaceutical company. From May 2006 to March 2007, she was the Chief Executive Officer and a director of YM Biosciences US and President, YM Biosciences, Inc., a global biopharmaceutical organization with three late-stage oncology programs. Prior to joining YM Biosciences in 2006, she was President, Chief Executive Officer and director of Eximias Pharmaceutical Corporation, also a late-stage biopharmaceutical company focused on oncology. From 2001 to 2004, Ms. Schulze was Chief Operating Officer and Deputy Chief Executive Officer of Aventis Behring LLC, a fully independent biologics subsidiary of Aventis, and from 1997 to 2001, she was Senior Executive Vice President and Chief Commercial Officer. From 1995 to 1997, she was Corporate Vice President of Allegiance Healthcare Corporation, where she led the creation and management of the Cost Management Services group of divisions. From 1979 to 1995, Ms. Schulze held multiple positions within Baxter Healthcare Corporation focused on the global development and commercialization of chronic therapies, most recently as President of the US Managed Care division and President of Renal Division Europe. Ms. Schulze has served on multiple private and public boards.

Franklin Witney

Dr. Frank R. Witney is an Independent Director of Cerus Corporation. Prior to his current position at Affymetrix, Dr. Witney’s appointment to the Board, filling the vacancy left by our former director and Chair of the Board, B.J. Cassin, in part due to his extensive experience in the life science industry, his expertise in corporate strategy and the commercialization of products, and the depth of his scientific background. Dr. Witney has served as President, Chief Executive Officer and a director of Affymetrix, Inc., a provider of life science products and molecular diagnostic products, since July 2011. Dr. Witney served as President and Chief Executive Officer of Dionex Corporation, a provider of analytical instrumentation and related accessories and chemicals, from April 2009 until its acquisition by Thermo Fisher Scientific, Inc. in May 2011. Between December 2008 and April 2009, Dr. Witney served as Affymetrix’s Executive Vice President and Chief Commercial Officer. Prior to that, Dr. Witney served as President and Chief Executive Officer of Panomics, Inc. from July 2002 to December 2008. Dr. Witney was a post-doctoral fellow at the National Institutes of Health.

Lainie Corten